| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| Gesamt | 3.298.051.614 $ | +820.702.433 $ | +35,7 % | 33 | 2.679.121.858 $ | +683.858.679 $ | +56,2 % | 33 | 2.024.517.832 $ | +629.729.845 $ | +42,5 % | 27 | |||
| Apogee Therapeutics, Inc. | APGE | → 0 | 1.127.318.496 $ | +412.435.667 $ | +57,7 % | 1 | 714.882.829 $ | +73.806.960 $ | +11,5 % | 1 | 641.075.869 $ | +303.636.226 $ | +90,0 % | 1 | |
| Oruka Therapeutics, Inc. | ORKA | → 0 | Neutral | 394.805.893 $ | +191.325.500 $ | +94,0 % | 1 | 203.480.393 $ | +77.741.540 $ | +61,8 % | 1 | 125.738.853 $ | +45.964.583 $ | +57,6 % | 1 |
| Erasca, Inc. | ERAS | → 0 | Neutral | 327.777.996 $ | +62.704.098 $ | +23,7 % | 1 | 265.073.898 $ | +198.645.549 $ | +299,0 % | 1 | 66.428.349 $ | +27.499.908 $ | +70,6 % | 1 |
| Spyre Therapeutics, Inc. | SYRE | → 0 | Schwach | 265.048.073 $ | +79.154.076 $ | +42,6 % | 1 | 185.893.997 $ | +65.158.721 $ | +54,0 % | 1 | 120.735.276 $ | +75.727.168 $ | +168,3 % | 1 |
| KalVista Pharmaceuticals, Inc. | KALV | → 0 | 130.331.383 $ | +21.658.275 $ | +19,9 % | 1 | 108.673.108 $ | +26.714.071 $ | +32,6 % | 1 | |||||
| Viridian Therapeutics, Inc.\DE | VRDN | → 0 | Neutral | 59.847.935 $ | -16.097.853 $ | -21,2 % | 1 | 75.945.788 $ | -44.884.116 $ | -37,1 % | 1 | 120.829.904 $ | +37.041.044 $ | +44,2 % | 1 |
| Dianthus Therapeutics, Inc. /DE/ | DNTH | → 0 | Schwach | 115.026.400 $ | +16.000.800 $ | +16,2 % | 1 | 99.025.600 $ | +57.815.600 $ | +140,3 % | 1 | 41.210.000 $ | +3.402.402 $ | +9,0 % | 1 |
| OCULAR THERAPEUTIX, INC | OCUL | → 0 | Sehr schwach | 101.606.813 $ | +13.968.350 $ | +15,9 % | 1 | 87.638.463 $ | -1.172.278 $ | -1,3 % | 1 | 88.810.741 $ | -65.046.750 $ | -42,3 % | 1 |
| Damora Therapeutics, Inc. | DMRA | → 0 | Neutral | 93.729.506 $ | +396.395 $ | +0,4 % | 1 | 93.333.111 $ | +93.333.111 $ | 1 | |||||
| Savara Inc | SVRA | → 0 | Schwach | 90.835.009 $ | +15.812.561 $ | +21,1 % | 1 | 75.022.448 $ | -7.832.013 $ | -9,5 % | 1 | 82.854.461 $ | +37.583.137 $ | +83,0 % | 1 |
| Cogent Biosciences, Inc. | COGT | → 0 | Neutral | 63.551.824 $ | -13.428.176 $ | -17,4 % | 1 | 76.980.000 $ | +5.940.000 $ | +8,4 % | 1 | 71.040.000 $ | +13.600.000 $ | +23,7 % | 1 |
| Jade Biosciences, Inc. | JBIO | → 0 | Schwach | 71.556.488 $ | +26.310.374 $ | +58,1 % | 1 | 45.246.114 $ | -4.444.103 $ | -8,9 % | 1 | 49.690.217 $ | +21.898.476 $ | +78,8 % | 1 |
| Enliven Therapeutics, Inc. | ELVN | → 0 | Neutral | 26.711.298 $ | -40.960.877 $ | -60,5 % | 1 | 67.672.175 $ | +17.986.678 $ | +36,2 % | 1 | 49.685.497 $ | -16.357.499 $ | -24,8 % | 1 |
| CytomX Therapeutics, Inc. | CTMX | → 0 | Schwach | 18.682.965 $ | -28.233.018 $ | -60,2 % | 1 | 46.915.983 $ | -19.376.007 $ | -29,2 % | 1 | 66.291.990 $ | +16.650.805 $ | +33,5 % | 1 |
| Maze Therapeutics, Inc. | MAZE | → 0 | Neutral | 47.804.695 $ | -16.020 $ | -0,0 % | 1 | 47.820.715 $ | -16.336.499 $ | -25,5 % | 1 | 64.157.214 $ | +32.243.374 $ | +101,0 % | 1 |
| Vor Biopharma Inc. | VOR | → 0 | Neutral | 55.998.047 $ | +1.733.780 $ | +3,2 % | 1 | 54.264.267 $ | +28.839.808 $ | +113,4 % | 1 | 25.424.459 $ | +1.066.115 $ | +4,4 % | 1 |
| Oric Pharmaceuticals, Inc. | ORIC | → 0 | Schwach | 46.783.055 $ | -7.948.368 $ | -14,5 % | 1 | 54.731.423 $ | +8.299.862 $ | +17,9 % | 1 | 46.431.561 $ | -32.731.059 $ | -41,3 % | 1 |
| Dyne Therapeutics, Inc. | DYN | → 0 | Neutral | 48.282.608 $ | +8.869.565 $ | +22,5 % | 1 | 39.413.043 $ | -3.108.695 $ | -7,3 % | 1 | 42.521.738 $ | +15.021.739 $ | +54,6 % | 1 |
| RELMADA THERAPEUTICS, INC. | RLMD | → 0 | Neutral | 47.362.591 $ | +13.652.666 $ | +40,5 % | 1 | 33.709.925 $ | +33.709.925 $ | 1 | |||||
| enGene Therapeutics Inc. | ENGN | → 0 | Schwach | 32.493.329 $ | -10.592.539 $ | -24,6 % | 1 | 43.085.868 $ | +8.618.860 $ | +25,0 % | 1 | ||||
| CRESCENT BIOPHARMA, INC. | CBIO | → 0 | Neutral | 38.404.368 $ | -789.423 $ | -2,0 % | 1 | 39.193.791 $ | +13.889.580 $ | +54,9 % | 1 | 25.304.211 $ | +8.802.508 $ | +53,3 % | 1 |
| Zura Bio Ltd | ZURA | → 0 | Neutral | 37.966.441 $ | -321.750 $ | -0,8 % | 1 | 38.288.191 $ | +10.279.788 $ | +36,7 % | 1 | 28.008.403 $ | +7.955.238 $ | +39,7 % | 1 |
| Adlai Nortye Group Ltd. | ANL | → 0 | Neutral | 36.946.407 $ | +14.714.308 $ | +66,2 % | 1 | 22.232.099 $ | +22.232.099 $ | 1 | |||||
| Upstream Bio, Inc. | UPB | → 0 | Neutral | 31.746.441 $ | +9.751.946 $ | +44,3 % | 1 | ||||||||
| Helus Pharma Inc. | HELP | → 0 | Neutral | 25.459.433 $ | +6.971.494 $ | +37,7 % | 1 | 18.487.939 $ | -12.925.306 $ | -41,1 % | 1 | 31.413.245 $ | +31.413.245 $ | 1 | |
| TENAX THERAPEUTICS, INC. | TENX | → 0 | Schwach | 26.787.439 $ | +23.456.481 $ | +704,2 % | 1 | ||||||||
| Cullinan Therapeutics, Inc. | CGEM | → 0 | Neutral | 25.129.163 $ | +5.519.860 $ | +28,1 % | 1 | 19.609.303 $ | +5.326.665 $ | +37,3 % | 1 | 14.282.638 $ | +6.099.446 $ | +74,5 % | 1 |
| Century Therapeutics, Inc. | IPSC | → 0 | Neutral | 21.304.347 $ | +1.652.173 $ | +8,4 % | 1 | 19.652.174 $ | +19.652.174 $ | 1 | |||||
| Artiva Biotherapeutics, Inc. | ARTV | → 0 | Schwach | 19.822.881 $ | +9.457.257 $ | +91,2 % | 1 | 10.365.624 $ | +3.460.573 $ | +50,1 % | 1 | 6.905.051 $ | +2.285.588 $ | +49,5 % | 1 |
| Surrozen, Inc./DE | SRZN | → 0 | Neutral | 16.424.559 $ | -2.012.721 $ | -10,9 % | 1 | 18.437.280 $ | +4.133.039 $ | +28,9 % | 1 | 14.304.241 $ | +6.148.925 $ | +75,4 % | 1 |
| ACHIEVE LIFE SCIENCES, INC. | ACHV | → 0 | Neutral | 17.964.239 $ | +17.964.239 $ | 1 | |||||||||
| Parabilis Medicines, Inc. | PBLS | → 0 | Neutral | 17.106.250 $ | +17.106.250 $ | 1 | |||||||||
| Septerna, Inc. | SEPN | → 0 | Neutral | 12.160.526 $ | -4.868.801 $ | -28,6 % | 1 | 17.029.327 $ | +5.540.029 $ | +48,2 % | 1 | ||||
| Korro Bio, Inc. | KRRO | → 0 | Schwach | 13.305.210 $ | +1.877.670 $ | +16,4 % | 1 | 11.427.540 $ | +11.427.540 $ | 1 | |||||
| Alto Neuroscience, Inc. | ANRO | → 0 | Neutral | 13.195.000 $ | +1.955.000 $ | +17,4 % | 1 | 11.240.000 $ | +11.240.000 $ | 1 | |||||
| X4 Pharmaceuticals, Inc | XFOR | → 0 | Neutral | 9.032.962 $ | +7.667.894 $ | +561,7 % | 1 | 1.365.068 $ | +1.365.068 $ | 1 | |||||
| Research Alliance Corp III | RACC | → 0 | Neutral | 3.210.000 $ | +3.210.000 $ | 1 | |||||||||
| CASI Pharmaceuticals, Inc. | CASIF | → 0 | 839.170 $ | -799.680 $ | -48,8 % | 1 | |||||||||
| InMed Pharmaceuticals Inc. | INM | → 0 | 50.662 $ | +50.662 $ | 1 | ||||||||||
| Gesamt | 3.298.051.614 $ | +820.702.433 $ | +35,7 % | 33 | 2.679.121.858 $ | +683.858.679 $ | +56,2 % | 33 | 2.024.517.832 $ | +629.729.845 $ | +42,5 % | 27 | |||